BioNexus Gene Lab Corp
For the period ended Dec 31, 2023. Filed Apr 16, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Apr 16, 2024
BGLC$0.89+7.5%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements
Our financial statements are contained in pages F-1 through F-21, which appear at the end of this Form 10-K Annual Report.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.